{
    "id": 3299,
    "fullName": "EGFR E868G",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR E868G lies within the protein kinase domain of the Egfr protein (UniProt.org). E868G results in increased Egfr activation in cell culture (PMID: 20942962), however, in another study, E868G induces similar cell proliferation and cell viability levels as wild-type Egfr in one of two different cell lines (PMID: 29533785), and therefore, its effect on Egfr protein function is unknown.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1956,
                    "pubMedId": 20942962,
                    "title": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20942962"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "E868G",
    "createDate": "02/22/2015",
    "updateDate": "10/31/2019",
    "referenceTranscriptCoordinates": {
        "id": 135619,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55191852A>G",
        "cDna": "c.2603A>G",
        "protein": "p.E868G",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6922,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) inhibited Egfr phosphorylation in cells expressing EGFR E868G in culture (PMID: 20942962).",
            "molecularProfile": {
                "id": 3115,
                "profileName": "EGFR E868G"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1956,
                    "pubMedId": 20942962,
                    "title": "Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/20942962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 3115,
            "profileName": "EGFR E868G",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135619,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55191852A>G",
            "cDna": "c.2603A>G",
            "protein": "p.E868G",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}